Moderna and OpenAI collaborating on AI tools for biotech operations, potential benefit for investors.

From The Motley Fool: 2024-05-12 09:25:00

Moderna and OpenAI are teaming up to incorporate artificial intelligence (AI) across the biotech’s operations, potentially benefiting investors. Moderna employees are already using AI tools for various tasks, including selecting vaccine doses for clinical trials. While the collaboration may not yield immediate financial gains, it could pave the way for future cost reductions and efficiencies with 14 new vaccines in the pipeline. This partnership is not a sole motive to invest in Moderna or Microsoft, but rather an innovation to monitor for the long-term biopharmaceutical development.



Read more at The Motley Fool: Moderna and OpenAI Are Teaming Up, but Does That Make the Stock a Buy?